350 results about "Glioma" patented technology

The invention relates to the technical field of boundary recognition, in particular to a glioma boundary recognition method and system based on image fusion, and the method comprises the following steps: obtaining a multi-modal brain image, constructing a fusion matrix, extracting the gray features of an edge region and an adjacent region, recognizing signal-noise abnormal points, and revising a judgment standard. And adjusting the path direction and reconstructing an edge communication structure, and generating a glioma boundary region map under fusion. According to the method, high-precision alignment among modals is realized through multi-modal image gray scale unification and registration processing, key details are expanded and focused by enhancing edges and regions, the recognition accuracy is improved, gray scale comparison between the edges and outer adjacent regions is introduced, the signal distinguishing capability is enhanced, misjudgment is avoided, judgment conditions are dynamically revised according to the signal-noise difference, and the accuracy of recognition is improved. The method enables the recognition standard to have local adaptability, combines the path change trend to reorder and connect edge points, guarantees the continuity of a boundary structure, integrally improves the accuracy and integrity of fuzzy boundary recognition, and enhances the glioma contour extraction effect.

The invention discloses a tumor space-occupying brain network neural image alignment method based on multi-modal fusion, and belongs to the technical field of medical image processing and artificial intelligence crossing. The method comprises the following core steps of multi-modal image heterogeneous feature decoupling, tumor occupation deformation field modeling, functional network topological structure maintenance, cross-modal feature adversarial alignment, dynamic deformation constraint optimization and clinical interpretability verification, and construction of a three-dimensional non-rigid registration network based on a double attention mechanism. And differential homeomorphic mapping of a tumor focus area and normal brain tissue is realized through the cascaded spatial transformation module. Aiming at the problems of insufficient multi-modal feature alignment and brain network topology distortion in the prior art, the invention provides a function connection constrained cross-modal fusion strategy, a graph convolution network is adopted to encode resting state function connection features, and network node displacement caused by tumor occupation is dynamically corrected in combination with deformable convolution and a bidirectional feature competition mechanism; a space consistency loss function based on white matter fiber bundle tracing is designed, and through diffusion tensor imaging feature guide structure-function bimodal joint optimization, the problems of insufficient registration precision in a focus area and whole brain network connection distortion of a traditional method are solved. Experiments show that the registration precision of the method in glioma cases reaches 0.82 mm and is improved by 37% compared with that of a traditional method, and dissection-function consistency of functional network reconstruction around tumors is remarkably improved.

The invention provides a SegTCLIP glioma segmentation method and system based on data amplification and a semantic map and application, and relates to the technical field of medical image processing and image segmentation, the method comprises the following steps: pre-processing a glioma image collected in advance, and carrying out missing mode filling processing on the pre-processed glioma image; performing feature extraction on the glioma image after filling processing and the corresponding text data, mapping the features into embedded vectors, and constructing an image-text mixed feature map; and calculating a pixel-text score graph based on the multi-modal pixel feature graph, and inputting the image-text mixed feature graph and the pixel-text score graph into a multi-modal decoding network for feature decoding to obtain a segmentation result. According to the method, the problems of glioma image modal deficiency and insufficient glioma image and text information fusion are solved, and meanwhile, the accuracy of complex glioma region segmentation is improved.

The invention provides a drug screening and curative effect evaluation method and system based on a glioma organ-like model, and relates to the technical field of biological material analys.The method includes the steps that a three-dimensional fluorescence image of the glioma organ-like model is collected, signal intensity analysis and compensation processing are carried out, a growth feature mapping model is constructed, and the three-dimensional fluorescence image of the glioma organ-like model is obtained; and phenotypic characteristics for representing the glioma organoid heterogeneity are obtained. Inputting the phenotypic characteristics into a drug response evaluation network, and calculating a drug sensitivity score; the drug molecular feature library and the drug collaborative analysis model are combined, the synergistic interaction index of different drug combinations is calculated, the optimal drug combination is screened, the drug administration dosage and the drug administration time sequence are determined in combination with phenotypic features, and finally an individualized treatment scheme is generated. According to the invention, the curative effect of the drug on the glioma organs can be effectively evaluated, and the optimal drug combination and administration scheme can be screened out, so that the accuracy and effectiveness of glioma treatment are improved.

The invention relates to a glioma radiotherapy effect prediction method based on habitat analysis imageomics, and belongs to the technical field of medical image artificial intelligence and tumor radiotherapy, and the method comprises the steps: collecting a multi-mode MRI image, a radiotherapy plan computed tomography CT image, a dose image and a local recurrence label before postoperative radiotherapy, and converting the images into a standard format; sequentially performing craniocerebral boning processing, N4 bias field correction, isotropic resampling, gray level normalization processing and image registration on the acquired image to obtain a preprocessed image; based on the planned target volume PTV, dividing the interior of the PTV into three types of physiological structure habitat areas and three types of physiological habitat areas; image omics features of the multi-mode MRI images are extracted in the PTV and all habitat areas, and an optimal feature subset is screened out; taking the screened optimal feature subset as an input, taking the local recurrence label as an output label, and selecting an optimal model; and generating an output result by using the optimal model.

The invention belongs to the technical field of medical image processing, and particularly relates to a glioma segmentation method based on a multimodal fusion network guided by anatomical symmetry, which comprises the following steps of: jointly inputting an FLAIR image, a T2 image, a T1 image and a T1c image of the same glioma into a trained image segmentation model, and outputting a predicted segmentation image by the trained image segmentation model, the prediction segmentation image is a glioma MRI image with three segmentation areas obtained through prediction, and the three segmentation areas are an edema area, an enhanced tumor area and a necrosis area respectively; the image segmentation model comprises an encoder, a jump connection part and a decoder; the encoder comprises an ASG module, the jump connection part comprises an IMP module, and the decoder comprises a CMF module. Through a three-module cooperation mechanism, the performance of tumor localization, cross-modal fusion, subregion segmentation and the like is improved, and a reliable image basis is provided for glioma operation plan formulation, prognosis evaluation and personalized treatment decision.

A boron carrying agent, a preparation method therefor, and a pharmaceutical formulation. The boron carrying agent contains compound 1, N-4-carboxyphenylboronic acid amide-threonine-phenylalanine-phenylalanine-tyrosine-glycine-glycine-serine-arginine-glycine-lysine-arginine-aspartic acid-aspartic acid-phenylalanine-lysine-threonine-glutamic acid-glutamic acid-tyrosine-cysteine, having a molecular formula of C114H158BN30O35S1 and a molecular weight of 2552.4, and further contains compound 2, N-4-carboxyphenylboronic acid amide-arginine-lysine-lysine-lysine-arginine-arginine-glutamine-arginine-arginine-arginine, and / or compound 3, N-4-carboxyphenylboronic acid amide-methionine-alanine-serine-methionine-threonine-glycine-glycine-glutamine-glutamine-methionine-glycine. Compounds 1-3 can serve as a targeted medicament for boron neutron capture therapy used for treating a cerebral glioma and a head and neck tumor.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention discloses a glioma radiotherapy postoperative risk assessment method based on a magnetic resonance image, particularly relates to the field of glioma radiotherapy patient health risk assessment, and is used for solving the problem that an existing assessment mode depends on manual interpretation and is difficult to predict bad clinical outcomes in advance. The method comprises the following steps: performing clinical data gridding reconstruction on a corticoid use cycle of a patient and tumor molecular typing, and combining morphological characteristics of an edema region in a magnetic resonance image to generate time-aligned clinical comprehensive characteristic vectors; mining a frequent association item set between the comprehensive feature vector and the pathological process to construct a mapping relation model; establishing a probability graph reasoning model of the bad outcome based on the pathological process vector sequence and the probability weight; and integrating the two types of models to form a causal reasoning network, and inputting a target patient feature vector to calculate an accumulated risk value of reaching a bad outcome. According to the method, an interpretable individual risk assessment result can be output, and a basis is provided for postoperative follow-up visit and intervention.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention particularly relates to application of phellinus igniarius exosomes in glioma treatment, an extraction method and a composition. The phellinus igniarius exosome is provided by taking phellinus igniarius as a raw material through operations such as soaking, crushing and centrifuging, and the phellinus igniarius exosome is verified to have anti-glioma activity in vitro. Based on the research result, the invention provides a new application of the phellinus igniarius-derived plant exosome in glioma treatment, and provides a potential active component with low cost for glioma drug development.

The invention belongs to the technical field of glioma image recognition, and discloses a glioma area rapid recognition method and system based on a medical image. The method comprises the following steps: acquiring a multi-modal image sequence of a brain to be detected; performing weighted fusion on the multi-modal image sequence to generate a fused image; performing gray asymmetry analysis on the fused image, and identifying an asymmetry salient region of the fused image; performing texture difference analysis on the fused image, and extracting a high-difference region of the fused image; performing spatial intersection operation on the asymmetric salient region and the high-difference region, and taking a spatial intersection operation result as a glioma suspicious region; and carrying out dynamic region growth segmentation on the glioma suspicious region, and rapidly outputting a glioma region boundary. According to the method, dual feature screening of gray and texture is combined with dynamic region growth segmentation, the tumor infiltration boundary is accurately captured, the positioning precision is improved, and the false positive rate of recognition is reduced.

The invention discloses application of a CXCL14 combined immune checkpoint inhibitor in treatment of spinal glioma. The immune checkpoint inhibitor is selected from a PD-1 inhibitor or a combination of the PD-1 inhibitor and a CTLA4 inhibitor. In-vivo and in-vitro experiments prove that the CXCL14 combined with the PD-1 inhibitor, the CXCL14 combined with the PD-1 inhibitor and the CTLA4 inhibitor can be used for remarkably inhibiting the growth of mutant spinal glioma and have a remarkable synergistic effect. The invention provides a new strategy for treatment of spinal glioma, and is widely applied clinically.

The invention discloses a glioma radiotherapy response prediction model construction method, a medium and a product, and relates to the technical field of medical instruments. According to the method, feature extraction and screening are carried out on the magnetic resonance images based on the radiomics technology, the sample data set is constructed, then the linear regression model is trained by using the sample data set, the trained linear regression model is obtained to serve as the glioma radiotherapy response prediction model, and glioma radiotherapy response prediction is realized.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

In one aspect, described herein is a method of treating a relapsed or refractory pediatric low-grade glioma (pLGG) in a subject in need thereof, comprising administering to the subject tovorafenib or a salt thereof, wherein the subject is 6 months of age or older. In some embodiments, the pediatric low-grade glioma (pLGG) harbors a BRAF fusion or rearrangement, or BRAF V600 mutation. In some embodiments, the method comprises administering a starting dose, a reduced dose, and optionally a further reduced dose.

The invention discloses a glioma postoperative radiotherapy prediction method based on imaging omics of multi-modal MRI, and relates to the technical field of medical image analysis, artificial intelligence and precise radiotherapy. Comprising the following steps: completing boning, bias field correction, gray normalization and spatial registration for three diffusion weighted imaging (DWI) images, CE-T1WI and FLAIR images and radiotherapy plan tomography (CT) images, and cutting a region of interest (ROI) slice in a planned target volume (PTV) region; an image encoder and a medical text encoder are used for image-text contrast learning, a two-stage domain adaptive model is constructed, three diffusion weighted imaging DWI image knowledge is migrated to a structural MRI image, soft voting fusion is performed on a multi-slice result in a reasoning stage, an individual recurrence probability is output, and an interpretable graph and a PDF report are generated in combination with Grad-CAM and t-SNE. The method has the advantages of high precision, strong generalization and good interpretability.

The invention discloses a tumor diagnosis method and system for generating a molecular spatial distribution diagram based on MRI (Magnetic Resonance Imaging), and belongs to the technical field of image data processing. The method comprises the following steps: constructing an MRI-pathological local matching data set; the Transform and the GAN are combined to construct a local MRI (Magnetic Resonance Imaging) to generate a small pathological graph model; and constructing and verifying a molecular spatial distribution diagram. According to the method, the histopathology is taken as a bridge, a two-layer mapping relation is constructed between the MRI and the molecular features, the global molecular features are estimated through local matching data, existing clinical resources are effectively utilized, and three-dimensional space distribution evaluation of the molecular features is indirectly achieved at low cost. And the constructed model can be used for pathological diagnosis in any region on the brain MRI sequence, so that the potential invasion region of the tumor can be explored, and reference is provided for the surgical resection range definition and treatment strategy planning of the glioma.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

The invention belongs to the technical field of medical artificial intelligence, and discloses a glioma feature prediction method and system based on multi-modal magnetic resonance and multi-task deep learning, and the method comprises the steps: processing input data through a modal completion module which combines knowledge distillation and modal existence coding, so as to deal with modal deficiency; after deep features are extracted by using a shared encoder, the deep features are sent to a hierarchical task gating prediction network, and the network performs gating modulation on post-stage task features through a pre-stage task result to realize task collaboration; and carrying out model training by adopting a self-adaptive loss function based on sample difficulty. Through the design, the accuracy and robustness of glioma segmentation, molecular marker prediction and lifetime prediction are improved, and the uncertainty score of the prediction result can be provided during reasoning.

The invention discloses a preparation method and application of a colloidal gold immunochromatography test strip for detecting IDH1 mutant protein, and belongs to the field of rapid immunodetection. The colloidal gold chromatography test strip comprises a bottom plate, a sample pad, a nitrocellulose membrane, a water absorption pad and colloidal gold, the nitrocellulose membrane is sequentially provided with a detection line T and a quality control line C in the flowing direction of a sample, the detection line T is coated with IDH1 mutant protein, and the quality control line C is coated with a second antibody corresponding to a monoclonal antibody of the IDH1 mutant protein. Clinical tumor tissue samples collected in real time in glioma resection surgery are treated, an object to be detected and an immune gold label are mixed, incubated and dropped in a test strip sample adding hole, and the object to be detected runs along the test strip under the driving of a buffer solution and generates visual color change. The test strip has the advantages of being rapid in reaction, easy and convenient to operate, convenient to carry, high in specificity and the like, makes up the blank of an IDH1 mutant protein concentration quantitative method, and has good clinical application value.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

Disclosed are methods of treating cancer in a subject comprising (i) administering a pharmaceutical composition comprising a therapeutically effective amount of a mutagenized IL 13 moiety (mIL 13); and then (ii) delivering a radiation therapy.

The invention provides an innovative model based on the correlation between the PLEKHA4 gene expression level and the low-grade glioma radiotherapy sensitivity and a prediction method. According to the model, a multi-factor Logistic regression analysis framework is constructed, and the PLEKHA4 gene expression level and key clinical pathological parameters are organically combined, so that a radiotherapy sensitivity prediction model is established. The method comprises a series of steps of sample collection, gene expression detection, clinical information collection, model calculation, result interpretation and the like, and can realize accurate prediction of radiotherapy response of low-grade glioma patients. Compared with the prior art, the method has the remarkable advantages of simplicity and convenience in operation, high prediction accuracy, high clinical transformability and the like. The method has great potential in the aspect of guiding individualized radiotherapy scheme formulation, can significantly improve the treatment effect, and has important value for medical application. Besides, the model can be optimized through further clinical verification, so that clinical practice can be better served, and the life quality and prognosis effect of patients are improved.

The invention belongs to the technical field of medical image processing, and relates to a brain tumor segmentation method based on three-axis context coding, which comprises the following steps: jointly inputting an FLAIR image, a T2 image, a T1 image and a T1ce image of the same glioma into a trained image segmentation model, and outputting a prediction segmentation image with a non-enhanced necrosis region, an edema region and an enhanced tumor region by the trained image segmentation model; the image segmentation model comprises an encoder and a decoder; the encoder comprises a TCE module, and the TCE module adaptively learns relative importance among an axial plane branch, a coronal plane branch and a sagittal plane branch to realize dynamic weighted fusion of multi-plane features. By pertinently solving the problems of insufficient anisotropic feature capture and poor multi-modal fusion adaptability, high-precision segmentation of a non-enhanced necrosis region, an edema region and an enhanced tumor region is realized, and reliable technical support is provided for clinical diagnosis and treatment planning of brain tumors.

The application belongs to the technical field of antitumor drugs, and discloses an iron complex as well as a preparation method and application thereof.The preparation steps of the iron complex are as follows: 1, reacting 2-hydrazinylbenzothiazole, a ketone compound and a solvent to obtain a ligand; and 2, reacting the ligand, ferric chloride and a solvent, and then cooling and crystallizing to obtain the iron complex.The obtained iron complex can effectively induce cancer cell ferroptosis, can effectively inhibit the growth of breast cancer, lung cancer, liver cancer or glioma, has high selectivity, has small toxicity to normal cell strains, and has better treatment effect compared with existing clinical drugs, such as cisplatin.